Open Peer Review on Qeios

Oncolytic Virus RP1

National Cancer Institute

Source

National Cancer Institute. <u>Oncolytic Virus RP1</u>. NCI Thesaurus. Code C158074.

A genetically modified oncolytic viral strain of the herpes simplex type 1 (HSV-1) virus, with potential oncolytic, immunostimulating and antineoplastic activities. Upon administration, the oncolytic virus RP1 specifically targets, infects and replicates in tumor cells only while not infecting normal, healthy cells. This induces tumor cell lysis. The released virus particles, infect and replicate in neighboring tumor cells, thereby further killing tumor cells. The released tumor-associated antigens (TAAs) from the tumor cells activate the immune system to exert an anti-tumor immune response against the tumor cells, thereby further killing tumor cells. The virus itself also elicits a tumor-specific systemic immune and cytotoxic T-lymphocyte (CTL) response, thereby killing nearby non-infected tumor cells. In RP1, ICP34.5 and 47 proteins of the HSV1 strain have been deleted; RP1 expresses a fusogenic protein for optimal tumor cell infection and killing.